Mary S. Brady, MD; Memorial Sloan-Kettering Cancer Center, New York, New York; Nikki S. Noce, New York University Medical Center, New York, New York

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »

Mark S. Nestor, MD, PhD, Center for Clinical and Cosmetic Research, Aventura, Florida; Glynis R. Ablon, MD, Ablon Skin Institute, Manhattan Beach, California; Mark A. Stillman, PhD, Center for Clinical and Cosmetic Research, Aventura, Florida

Disclosure: Dr. Nestor has received research grant support from and is a consultant and speaker for Medicis. Dr. Ablon has been a consultant for Medicis. Dr. Stillman reports no relevant conflicts of interest. This study was funded by an unrestricted educational grant from ThermoTek. The product used in this study was supplied by Medicis Aesthetics Incorporated. Read the rest of this article »

Ashley Collins, MD; Department of Biochemistry, North Carolina State University; Adnan Nasir, MD, Department of Dermatology, University of North Carolina, Chapel Hill, North Carolina

Abstract
Nanotechnology is a rapidly growing discipline that capitalizes on the unique properties of matter engineered on the nanoscale. Vehicles incorporating nanotechnology have led to great strides in drug delivery, allowing for increased active ingredient stability, bioavailability, and site-specific targeting. Botulinum toxin has historically been used for the correction of neurological and neuromuscular disorders, such as torticollis, blepharospasm, and strabismus. Recent dermatological indications have been for the management of axillary hyperhydrosis and facial rhytides. Traditional methods of botulinum toxin delivery have been needle-based. These have been associated with increased pain and cost. Newer methods of botulinum toxin formulation have yielded topical preparations that are bioactive in small pilot clinical studies. While there are some risks associated with topical delivery, the refinement and standardization of delivery systems and techniques for the topical administration of botulinum toxin using nanotechnology is anticipated in the near future.  (J Clin Aesthetic Dermatol. 2010;3(3):35–39.) Read the rest of this article »

Gao Yang, MD, Laser Center, Jinshan Hospital, Fudan University, Shanghai, China; Leihong Flora Xiang, MD, PhD Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China; Michael H. Gold, MD, Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, Tennesee; Vanderbilt University School of Medicine, Department of Dermatology; Vanderbilt University School of Medicine, School of Nursing, Nashville, Tennesee; Huashan Hospital, Fudan University, Shanghai, China; Number One Hospital, China Medical University, Shenyang, China Read the rest of this article »

Morgan McCarty (MS4);
James Q. Del Rosso, DO, FAOCD

Section Editor: James Q. Del Rosso, DO, FAOCD

Ms. McCarty (MS4) is from Midwestern University AZCOM, Glendale, Arizona. Dr. Del Rosso is Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada. Disclosure: Ms. McCarty and Dr. Del Rosso report no relevant conflicts of interest. Read the rest of this article »

Jacquelyn Levin, DO; James Q. Del Rosso, DO, FAOCD; Saira B. Momin, DO

Dr. Levin is from the Mohave Skin & Cancer Clinics, Dermatology Research Center, Las Vegas, Nevada; Dr. Del Rosso is Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada; Dr. Momin is Chief Dermatology Resident (PGY-4), Valley Hospital Medical Center, Las Vegas, Nevada. Read the rest of this article »

Jorge M. Tagle, MD; Pedro Cervantes Macchetto, MD*; Rosa Margarita Durán Páramo, MD*

Dr. Tagle is Plastic and Reconstructive Surgeon, International Board of Plastic, Aesthetic and Reconstructive Surgery, European Society of Plastic and Reconstructive Surgery Documentation; Dr. Mcchetto is in Private Practice, General Hospital of Tijuana, Tijuana, Mexico; Dr. Páramo is in Private Practice.

Disclosure: The authors report no relevant conflicts of interest. *At the time of the study, Dr. Macchetto was a Surgeon at the Hospital del Prado, Tijuana, B.C. Mexico, and Dr. Paramo was with Conasida, a Mexican government agency dedicated to the fight against AIDS. Read the rest of this article »

Michael H. Gold, MD; Amy Foster, RN; Julie A. Biron, BS

Dr. Gold is Medical Director, Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, Tennessee; Assistant Clinical Professor, Vanderbilt University Medical School, Nashville, Tennessee; Visiting Professor, Fudan University (Shanghai Medical University), Shanghai, China, China Medical University, Shenyang, China; Ms. Foster and Ms. Biron are from the Tennessee Clinical Research Center, Nashville, Tennessee Read the rest of this article »

Patricia Gilligan, BS; Anthony Vander Horst, MA; Matthew J. Zirwas, MD

Dr. Zirwas is Assistant Professor of Dermatology, The Ohio State University, Columbus, Ohio. Ms. Gilligan is from The Ohio State University College of Medicine. Mr. Vander Horst is from the Department of Education—Quantitative Section, The Ohio State University, Columbus, Ohio. The authors report no relevant conflicts of interest. Read the rest of this article »

Sarah Grim Hostetler, MD, Division of Dermatology, Ohio State University College of Medicine; Benjamin Kaffenberger, BS, The Ohio State University College of Medicine; Todd Hostetler, MD, Division of Allergy and Immunology, The Ohio State University Medical Center, Columbus, Ohio; Matthew J. Zirwas, MD, Division of Dermatology, Ohio State University College of Medicine

Abstract
Atopic dermatitis is a common, chronic skin condition. A subpopulation of patients may have cutaneous exposure to common airborne proteins exacerbating their disease through direct proteolytic activity, direct activation of proteinase-activated receptor-2 itch receptors, and immunoglobulin E binding. The most common airborne proteins significant in atopic dermatitis include house dust mites, cockroach, pet dander, and multiple pollens. The literature on atopy patch testing, skin-prick testing, and specific IgE is mixed, with greater support for the use of atopy patch test. Patients with airborne proteins contributing to their disease typically have lesions predominately on air-exposed skin surfaces including the face, neck, and arms; a history of exacerbations after exposure to airborne proteins; severe disease resistant to conventional therapies; and concurrent asthma. Treatment strategies include airborne protein avoidance, removal of airborne proteins from the skin, and barrier repair. Further research is needed to establish the benefit of allergen-specific immunotherapy.  (J Clin Aesthetic Dermatol. 2010;3(1):22–31.) Read the rest of this article »